Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Antibody and Peptide Therapeutics

Mark Cragg's Biography



Mark Cragg, Professor, University of Southampton

Mark Cragg is a Professor in Experimental Cancer Biology at the Cancer Sciences Division of Southampton University School of Medicine, UK. He obtained his PhD in 1998 and did his postdoctoral studies with Martin Glennie in Southampton and then Andreas Strasser at the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. He has published over 60 papers, many in high impact journals such as the Journal of Clinical Investigation, PNAS, Plos Medicine and Blood and leads a dynamic research group interested in all aspects of how therapeutics such as antibodies result in tumour regression and how they can be improved.

Mark Cragg Image

Improving on Rituximab – Selecting CD20 mAb for the Future

Thursday, 21 July 2011 at 16:00

Add to Calendar ▼2011-07-21 16:00:002011-07-21 17:00:00Europe/LondonImproving on Rituximab – Selecting CD20 mAb for the FutureSELECTBIOenquiries@selectbiosciences.com

The anti-CD20 mAb Rituximab, has transformed treatment of lymphoma. Despite this success a substantial proportion of B-cell lymphomas are refractory. Here, we present the case for focusing on so-called type II anti-CD20 mAb in the future.


Add to Calendar ▼2011-07-20 00:00:002011-07-21 00:00:00Europe/LondonAntibody and Peptide TherapeuticsSELECTBIOenquiries@selectbiosciences.com